Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development, and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Biodesix Inc.

Biodesix, Inc. ( ($BDSX) ) has released its Q3 earnings. Here is a breakdown of the information Biodesix, Inc. presented to its investors. Biodesix...

Biodesix Reports Strong Q3 2025 Revenue Growth

Canaccord Genuity analyst Kyle Mikson CFA maintained a Buy rating on Biodesix today and set a price target of $6.73. The company’s shares closed la...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BDSX	$6.83	+4.92%	26.08K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BDSX	$6.83	+4.9%	26.08K
3
4
5
6

BDSX

BDSX

No Data Available

Get Biodesix Inc. Data in Excel

Get Biodesix Inc. Data in Excel